To complement the siRNA experiments, we transiently re-expressed ARID1A in ARID1A-mutant TOV21G ovarian cancer cells and found that ARID1A re-expression resulted in increased resistance of the cells to treatment with elesclomol (Figure 4a and 4b). This evidence concerns the gene ARID1A and ovarian carcinoma.